{
  "abstract": "Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment of refractory hematologic malignancies, but its long-term safety has become an increasing concern. Secondary primary malignancies (SPM) following CAR-T-cell therapy have emerged as a growing focus of clinical and translational research. Evidence to date suggests that the incidence of different types of SPMs vary, with a two-year cumulative incidence ranging from approximately 0.08% to 8% and a median time to onset of 9.7 to 26.4 months, predominantly involving myeloid malignancies such as myelodysplastic syndromes and acute myeloid leukemia, while solid tumors and rare T-cell lymphomas have also been reported. CAR transgenes have been detected in only a minority of T-cell lymphoma cases. The mechanisms involved vector-related genomic integration risks, genotoxic stress from prior chemotherapy or hematopoietic stem cell transplantation, immune dysregulation, and clonal hematopoietic expansion. Future research may focus on developing safer gene-editing technologies, moving CAR-T-cell therapy to earlier treatment lines to reduce cumulative toxicity from prior therapies, implementing genetic risk screening before treatment, and establishing long-term systematic monitoring after therapy. By optimizing full-process management, the risk of SPM can be minimized, thereby improving the long-term safety of CAR-T-cell therapy while maintaining its therapeutic efficacy.",
  "abstract_shown": true,
  "affiliations": [
    "State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China."
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "R N Li"
    },
    {
      "affs": [
        0
      ],
      "name": "W Y Wang"
    },
    {
      "affs": [
        0
      ],
      "name": "F Yang"
    },
    {
      "affs": [
        0
      ],
      "name": "L L Zhang"
    },
    {
      "affs": [
        0
      ],
      "name": "J Shi"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4mf8kjsdr9q6k.bib",
  "cited_by": 0,
  "doi": "10.3760/cma.j.cn121090-20260118-00036",
  "fulltext_url": "https://europepmc.org/articles/PMC13669432",
  "id": "4mf8kjsdr9q6k",
  "issns": [
    "0253-2727",
    "2707-9740"
  ],
  "landing_url": "https://europepmc.org/article/MED/42851188",
  "language": "chi",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|CAR-T cell therapy research"
    ]
  ],
  "openalex": "W7221119744",
  "pdf_url": "https://europepmc.org/articles/PMC13669432?pdf=render",
  "pmcid": "PMC13669432",
  "pmid": "42851188",
  "published": "2026-08-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/4mf8kjsdr9q6k.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:18:10Z",
      "native_id": "MED:42851188",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42851188"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|CAR-T cell therapy research",
      "subfield": "oncology"
    }
  ],
  "title": "[The risk and management strategies for second primary tumor after CAR-T cell therapy].",
  "title_text": "[The risk and management strategies for second primary tumor after CAR-T cell therapy].",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:18:10Z",
  "url": "https://research.draconitic.com/paper/4mf8kjsdr9q6k",
  "venue": "Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi",
  "versions": []
}